Combination of cilostazol and clopidogrel attenuates Rat critical limb ischemia

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Sheu, Jiunn Jye ^a   Lin, Kun Chen ^a   Tsai, Ching Yen ^b   Tsai, Tzu Hsien ^a   Leu, Steve ^c   Yen, Chia Hung ^d   Chen, Yung Lung ^a   Chang, Hsueh Wen ^e   Sun, Cheuk Kwan ^f   Chua, Sarah ^a   Yang, Jenq Lin ^c   Yip, Hon Kan ^a,c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^e NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^f I SHOU UNIVERSITY   (Taiwan)

Author keywords

Angiogenesis; Apoptosis; Critical limb ischemia; Inflammation; Pharmacomodulation

Indexed keywords

CASPASE 3; CD31 ANTIGEN; CD68 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME C; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE B; INTERLEUKIN 10; MESSENGER RNA; MICRORNA; MICRORNA 206; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BAX; PROTEIN BCL 2; STEM CELL ANTIGEN 1; STEM CELL FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD FLOW; BLOOD SAMPLING; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; CYTOSOL; DRUG MEGADOSE; ENDOTHELIAL PROGENITOR CELL; HEART MUSCLE; IMMUNOFLUORESCENCE TEST; INFLAMMATION; LASER DOPPLER FLOWMETRY; MALE; MUSCLE INJURY; NONHUMAN; OXIDATIVE STRESS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; SKELETAL MUSCLE;

ANIMALS; BLOTTING, WESTERN; DRUG THERAPY, COMBINATION; EXTREMITIES; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; ISCHEMIA; MALE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; TETRAZOLES; TICLOPIDINE;

EID: 84864959531     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-164     Document Type: Article

References (37)

1. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001, 344:1608-1621. 10.1056/NEJM200105243442108, 11372014.
2. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, Powe NR, Siscovick D. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 1999, 19:538-545. 10.1161/01.ATV.19.3.538, 10073955.
3. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001, 286:1317-1324. 10.1001/jama.286.11.1317, 11560536.
4. Ouriel K. Peripheral arterial disease. Lancet 2001, 358:1257-1264. 10.1016/S0140-6736(01)06351-6, 11675083.
5. Dormandy JA, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg 1999, 12:142-147.
6. Yip HK, Wu CJ, Hang CL, Chang HW, Hung WC, Yeh KH, Yang CH. Serial changes in platelet activation in patients with unstable angina following coronary stenting: evaluation of the effect of clopidogrel loading dose in inhibiting platelet activation. Circ J 2005, 69:1208-1211. 10.1253/circj.69.1208, 16195618.
7. Yip HK, Chen SS, Liu JS, Chang HW, Kao YF, Lan MY, Chang YY, Lai SL, Chen WH, Chen MC. Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation. Stroke 2004, 35:1683-1687. 10.1161/01.STR.0000131658.80951.c3, 15155956.
8. Mehta SR, Yusuf S. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000, 21:2033-2041.
9. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med 2004, 164:2106-2110. 10.1001/archinte.164.19.2106, 15505123.
10. Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF, Polson JB. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isoenzyme families PDE III and PDE IV to attenuate proliferation rate of vascular smooth muscle cells. Biochem Pharmacol 1994, 48:827-835.
11. Kubota Y, Kichikawa K, Uchida H. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries: an experimental study. Invest Radiol 1995, 30:532-537. 10.1097/00004424-199509000-00004, 8537210.
12. Douglas JS, Holmes DR, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS. Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005, 112:2826-2832. 10.1161/CIRCULATIONAHA.104.530097, 16246948.
13. Sabatine MS, Hamdalla HN, Mehta SR, Fox KA, Topol EJ, Steinhubl SR, Cannon CP. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. Am Heart J 2008, 155:910-917. 10.1016/j.ahj.2007.11.020, 18440341.
14. Lemesle G, Torguson R, Bonello L, de Labriolle A, Maluenda G, Ben-Dor I, Collins SD, Syed AI, Xue Z, Satler LF, Pichard AD, Waksman R. Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents. Euro Intervention 2011, 6:1053-1059.
15. Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, Cheong SS, Kim JJ, Park SW, Park SJ. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc Interv 2008, 1:494-503. 10.1016/j.jcin.2008.06.011, 19463351.
16. Yip HK, Chang LT, Chang WN, Lu CH, Liou CW, Lan MY, Liu JS, Youssef AA, Chang HW. Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke. Stroke 2008, 39:69-74. 10.1161/STROKEAHA.107.489401, 18063830.
17. Yip HK, Wu CJ, Chang HW, Yang CH, Yeh KH, Chua S, Fu M. Levels and values of serum high-sensitivity C-reactive protein within six hours after the onset of an acute myocardial infarction. Chest 2004, 126:1417-1422. 10.1378/chest.126.5.1417, 15539707.
18. Yip HK, Sun CK, Chang LT, Wu CJ. Strong correlation between serum levels of inflammatory mediators and their distribution in infarct coronary. Circ J 2006, 70:838-845. 10.1253/circj.70.838, 16799235.
19. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994, 89:36-44. 10.1161/01.CIR.89.1.36, 8281670.
20. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115-126. 10.1056/NEJM199901143400207, 9887164.
21. De Scheerder I, Vandekerckhove J, Robbrecht J, Algoed L, De Buyzere M, De Langhe J, De Schrijver G, Clement D. Post cardiac injury syndrome and an increased humoral immune response against the major contractile proteins (actin and myosin). Am J Cardiol 1985, 56:631-633. 10.1016/0002-9149(85)91024-0, 4050699.
22. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002, 53:31-47. 10.1016/S0008-6363(01)00434-5, 11744011.
23. Lambert JM, Lopez EF, Lindsey ML. Macrophage roles following myocardial infarction. Int J Cardiol 2008, 130:147-158. 10.1016/j.ijcard.2008.04.059, 2857604, 18656272.
24. Leu S, Lin YC, Yuen CM, Yen CH, Kao YH, Sun CK, Yip HK. Adipose-derived mesenchymal stem cells markedly attenuate brain infarct size and improve neurological function in rats. J Transl Med 2010, 8:63. 10.1186/1479-5876-8-63, 2913939, 20584315.
25. Sheu JJ, Chua S, Sun CK, Chang LT, Yen CH, Wu CJ, Fu M, Yip HK. Intra-coronary administration of cyclosporine limits infarct size, attenuates remodeling and preserves left ventricular function in porcine acute anterior infarction. In J Cardiol 2011, 147:79-87.
26. Sun CK, Lee FY, Sheu JJ, Yuen CM, Chua S, Chung SY, Chai HT, Chen YT, Kao YH, Chang LT, Yip HK. Early combined therapy with cilostazol and bone marrow-derived endothelial progenitor cells markedly attenuates pulmonary arterial hypertension in rats. J Pharmacol Exp Ther 2009, 330:718-726. 10.1124/jpet.109.154328, 19528354.
27. Yip HK, Chang LT, Sun CK, Yang CH, Hung WC, Cheng CI, Chua S, Yeh KH, Wu CJ, Fu M. Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting. Am J Cardiol 2006, 97:192-194. 10.1016/j.amjcard.2005.08.023, 16442361.
28. Cekici Y, Korkmaz H, Celik A, Bilen MN, Bulut M, Akbulut M. The effect of the duration of clopidogrel use on hsCRP levels after stenting the target vessel in patients with acute coronary syndrome. Clin Invest Med 2011, 34:E211.
29. Hu H, Batteux F, Chereau C, Kavian N, Marut W, Gobeaux C, Borderie D, Dinh-Xuan AT, Weill B, Nicco C. Clopidogrel protects from cell apoptosis and oxidative damage in a mouse model of renal ischaemia-reperfusion injury. J Pathol 2011, 225:265-275. 10.1002/path.2916, 21630270.
30. Tsai TH, Lin YC, Sun CK, Chung SY, Chai HT, Yang CH, Chen SM, Hang CL, Chen CJ, Chua S, Wu CJ, Leu S, Yip HK. Prognostic value of circulating dead monocytes in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Cardiology 2010, 117:131-139. 10.1159/000320208, 20975265.
31. Shin HK, Lee HR, Lee DH, Hong KW, Lee JH, Park SY, Lee SJ, Lee JS, Lee WS, Rhim BY, Kim CD. Cilostazol enhances neovascularization in the mouse hippocampus after transient forebrain ischemia. J Neurosci Res 2010, 88:2228-2238. 10.1002/jnr.22376, 20175201.
32. Kawabe-Yako R, Masaaki I, Masuo O, Asahara T, Itakura T. Cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury model. PLoS One 2011, 6:e24646. 10.1371/journal.pone.0024646, 3171459, 21931795.
33. Sahara M, Sata M, Morita T, Nakajima T, Hirata Y, Nagai R. A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1/vascular endothelial growth factor pathway. Arterioscler Thromb Vasc Biol 2010, 30:1315-1324. 10.1161/ATVBAHA.109.201327, 20413734.
34. Afek A, Kogan E, Maysel-Auslender S, Mor A, Regev E, Rubinstein A, Keren G, George J. Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice. Microvasc Res 2009, 77:364-369. 10.1016/j.mvr.2009.01.009, 19323972.
35. França CN, Pinheiro LF, Izar MC, Brunialti MK, Salomão R, Bianco HT, Kasmas SH, Barbosa SP, de Nucci G, Fonseca FA. Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. Circ J 2012, 76:729-736. 10.1253/circj.CJ-11-1145, 22214900.
36. Schäfer A, Fraccarollo D, Pförtsch S, Loch E, Neuser J, Vogt C, Bauersachs J. Clopidogrel improves endothelial function and NO bioavailability by sensitizing adenylyl cyclase in rats with congestive heart failure. Basic Res Cardiol 2011, 106:485-494. 10.1007/s00395-011-0153-4, 21287353.
37. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL, Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011, 365:993-1003. 10.1056/NEJMoa1105335, 21899409.